In NSCLC, Tranilast inhibits IL-6 secretion by CAFs, blocks CAF-induced upregulation of the STAT3 signaling pathway, reduces EMT, and reverses CAF-mediated resistance of NSCLC to osimertinib/selumetinib (Ochi et al., 2022). The gene discussed is IL6; the disease is non-small cell lung carcinoma.